Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Hypertriglyceridaemia? 140 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 140 reports of Hypertriglyceridaemia have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.2% of all adverse event reports for DOXORUBICIN.

140
Reports of Hypertriglyceridaemia with DOXORUBICIN
0.2%
of all DOXORUBICIN reports
14
Deaths
45
Hospitalizations

How Dangerous Is Hypertriglyceridaemia From DOXORUBICIN?

Of the 140 reports, 14 (10.0%) resulted in death, 45 (32.1%) required hospitalization, and 22 (15.7%) were considered life-threatening.

Is Hypertriglyceridaemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 140 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Hypertriglyceridaemia?

PEGASPARGASE (399) VINCRISTINE (373) METHOTREXATE (372) DEXAMETHASONE (358) CYTARABINE (244) CYCLOPHOSPHAMIDE (191) QUETIAPINE (181) MERCAPTOPURINE (176) PREDNISONE (161) DAUNORUBICIN (143)

Which DOXORUBICIN Alternatives Have Lower Hypertriglyceridaemia Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Hypertriglyceridaemia Reports All Drugs Causing Hypertriglyceridaemia DOXORUBICIN Demographics